Circ: Newer LVAD costs drop but miss effectiveness mark Cardiovascular Business 3 in Circulation: Heart Failure, but it still fails to meet the standard threshold for being a cost-effect therapy. Nonetheless, the cost reductions obtained in a short window of time suggest these devices may reach that economic benchmark, ... |
